10-Q: Arbutus Biopharma Reports Q1 2025 Results, Streamlines Operations Amidst Patent Litigation

Arbutus Biopharma announces Q1 2025 financial results, details operational restructuring, and provides updates on ongoing patent infringement lawsuits against Moderna and Pfizer/BioNTech.

Summary

• Arbutus Biopharma Corporation reported a net loss of $24.5 million for the first quarter of 2025, compared to a net loss of $17.9 million for the same period in 2024.
• The company is focused on advancing its cHBV development programs and its in-house developed LNP delivery technology.
• Arbutus is pursuing patent infringement lawsuits against Moderna and Pfizer/BioNTech regarding their use of the company's LNP technology in COVID-19 mRNA vaccines.
• The company has filed five international lawsuits against Moderna in connection with the use of its LNP technology in Moderna's COVID-19 mRNA vaccines and RSV vaccines.
• Arbutus is developing imdusiran (AB-729) and AB-101 for the treatment of chronic hepatitis B (cHBV).
• The company completed enrollment in two Phase 2a clinical trials combining imdusiran with other agents.
• A restructuring in March 2025 included a 57% workforce reduction, exiting the corporate headquarters, and discontinuing in-house scientific research, resulting in a one-time charge of $12.4 million.
• As of March 31, 2025, Arbutus had $112.7 million in cash, cash equivalents, and investments in marketable securities.
• The company believes it has sufficient cash resources to fund its operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is actively pursuing patent litigation and streamlining operations, it also reported a higher net loss and implemented significant workforce reductions. The future outlook is cautiously optimistic, but the company faces several risks and uncertainties.

Positives

• Arbutus believes it has sufficient cash resources to fund its operations for at least the next 12 months.
• The company is actively pursuing patent infringement lawsuits to protect its LNP technology.
• The company is focused on its cHBV programs, including imdusiran and AB-101.
• The company expects to significantly reduce its net cash burn in 2025 compared to 2024.

Negatives

• The company reported a net loss of $24.5 million in Q1 2025, which is higher than the $17.9 million loss in Q1 2024.
• The company incurred a one-time restructuring charge of $12.4 million in Q1 2025.
• The company reduced its workforce by 57% in March 2025.

Risks

• The company's future funding needs may vary depending on the costs associated with prosecuting and enforcing patent claims.
• The company's future funding needs may vary depending on the revenue earned from collaborative partnerships and licensing agreements.
• The company's future funding needs may vary depending on the potential requirement to make milestone payments related to legacy agreements.
• The company's future funding needs may vary depending on the extent to which the company continues the development of its product candidates.
• The company's future funding needs may vary depending on the decisions, and the timing of decisions, made by health regulatory agencies regarding the company's technology and product candidates.
• The company's future funding needs may vary depending on competing products, product candidates and technological and market developments.

Future Outlook

With the organizational changes announced during the first quarter of 2025, and the company's ongoing cost management efforts, Arbutus expects to significantly reduce its net cash burn in 2025 when compared to 2024.

Management Comments

• The company remains committed to taking all legal actions necessary to defend and protect its intellectual property.
• The company's strategy is focused on maximizing opportunities for its cHBV development programs and its in-house developed LNP delivery technology.

Industry Context

Arbutus Biopharma is operating in the competitive biopharmaceutical industry, focusing on infectious diseases, particularly chronic hepatitis B (cHBV). The company's strategy involves developing a functional cure for cHBV patients using imdusiran as a potential cornerstone in a combination therapy. This approach aligns with the industry's broader efforts to develop more effective and finite treatments for HBV, aiming to prevent disease progression and reduce healthcare costs. The company's pursuit of patent infringement lawsuits against major players like Moderna and Pfizer/BioNTech highlights the importance of intellectual property in the biopharmaceutical sector, especially in innovative technologies like LNP delivery systems. These lawsuits reflect the industry's trend of protecting proprietary technologies that are crucial for developing advanced therapies, such as mRNA vaccines.

Comparison to Industry Standards

• Arbutus's approach to HBV treatment, focusing on functional cures through combination therapies, aligns with the broader industry trend of seeking more effective and durable treatments for chronic viral infections.
• The company's pursuit of patent litigation against Moderna and Pfizer/BioNTech is a common strategy in the biopharmaceutical industry to protect intellectual property rights, similar to actions taken by companies like Amgen and AbbVie to defend their patents.
• The company's restructuring efforts, including workforce reductions and facility closures, are not uncommon in the biopharmaceutical industry, especially for companies in the clinical stage facing financial constraints or strategic shifts, similar to actions taken by companies like Sanofi and Novartis.
• The company's cash position of $112.7 million is relatively modest compared to larger pharmaceutical companies but is typical for a clinical-stage biotech company, comparable to companies like BioCryst Pharmaceuticals and Sarepta Therapeutics.

Management Changes

Legal Proceedings

• Arbutus and Genevant filed five international lawsuits against Moderna seeking to enforce patents protecting their patented lipid nanoparticle technology.
• Arbutus and Genevant filed a lawsuit in the U.S. District Court for the District of New Jersey against Pfizer Inc. (Pfizer) and BioNTech SE (BioNTech) seeking damages for infringement of U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098 in the manufacture and sale of any COVID-19 mRNA-LNP vaccines.
• On April 5, 2018, Moderna and Merck, Sharp & Dohme Corporation (Merck) filed Notices of Opposition to Arbutus European patent EP 2279254 (the 254 Patent) with the European Patent Office (EPO), requesting that the 254 Patent be revoked in its entirety for all contracting states.
• On April 29, 2025, Moderna filed a revocation action on EPO patent EP 4 241 767 (the 767 patent) with the EPO, requesting that the patent be revoked in its entirety for all contracting states.

Stakeholder Impact

• Shareholders: The company's financial performance and strategic decisions, including the pursuit of patent litigation and restructuring efforts, may impact shareholder value.
• Employees: The workforce reduction of 57% in March 2025 has a significant impact on employees, with many losing their jobs.
• Customers: The company's focus on developing treatments for cHBV may benefit patients and healthcare providers.
• Suppliers: The company's restructuring efforts and changes in research and development activities may impact its relationships with suppliers.
• Creditors: The company's financial stability and cash position may affect its ability to meet its obligations to creditors.

Next Steps

• The court is expected to provide its ruling on the claim construction and issue a further scheduling order, including the date for trial, in 2025 for the Pfizer/BioNTech lawsuit.
• The company will continue to manage the IM-PROVE II clinical trial, subject to oversight by a joint development committee.
• Part 3 of the AB-101-001 clinical trial is ongoing.
• Modernas Statement of Defense is due on July 8, 2025 in the Unified Patent Court.
• Modernas deadline to provide facts, arguments, and evidence in support of invalidity is July 23, 2025.
• Oral proceedings are scheduled for January 15 and 16, 2026 for the Moderna and Merck European Oppositions.

Key Dates

Keywords

Arbutus Biopharma, LNP technology, Patent infringement, Imdusiran, AB-101, CHBV, Financial results, Restructuring, Clinical trials, Moderna, Pfizer, BioNTech